P-178 YI Capsule Endoscopy (CE) Aids in the Diagnosis and Management of Inflammatory Bowel Disease (IBD) in Pediatric Patients

2013 ◽  
Vol 19 ◽  
pp. S97-S98
Author(s):  
Kathleen Usmani ◽  
Rupinder Gill ◽  
Anupama Chawla
Keyword(s):  
Inflammatory Bowel Disease ◽  
Capsule Endoscopy ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Diagnosis And Management ◽  
Inflammatory Bowel

scholarly journals Pediatric Inflammatory Bowel Disease

2021 ◽  
Vol 3 (1) ◽  
pp. 11-17
Author(s):  
Rotondo-Trivette S ◽  
Michail S
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Adult Onset ◽  
Future Directions ◽  
Genetic Studies ◽  
Diagnosis And Management ◽  
Pediatric Inflammatory Bowel Disease ◽  
Inflammatory Bowel ◽  
Pediatric Onset

Inflammatory bowel disease is an important pediatric disease, with as many as 25% of cases presenting during childhood. In this article, we review the types, etiology epidemiology, presentation, diagnosis, and management of pediatric inflammatory bowel disease. We also highlight the unique aspects of pediatric-onset inflammatory bowel disease versus adult-onset and future directions in this field, such as the use of genetic studies and ultrasound for the management of pediatric patients with inflammatory bowel disease.

Nutritional status and food intake in pediatric patients with inflammatory bowel disease at diagnosis significantly differs from healthy controls

2019 ◽  
Vol 178 (10) ◽  
pp. 1519-1527 ◽  
Author(s):  
Sara Sila ◽  
Ivana Trivić ◽  
Ana Močić Pavić ◽  
Tena Niseteo ◽  
Sanja Kolaček ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Food Intake ◽  
Nutritional Status ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Healthy Controls ◽  
Inflammatory Bowel

scholarly journals Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease—A Single Center Case–Control Study

2021 ◽  
Vol 10 (14) ◽  
pp. 3177
Author(s):  
Edyta Szymanska ◽  
Maciej Dadalski ◽  
Joanna Sieczkowska-Golub ◽  
Dorota Jarzebicka ◽  
Monika Meglicka ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Case Control Study ◽  
Case Control ◽  
Chi Square ◽  
Infusion Reactions ◽  
Inflammatory Bowel ◽  
The Difference ◽  
Control Study

Background: Infusion reactions (IRs) are the most common adverse events (AEs) of infliximab (IFX) treatment in patients with inflammatory bowel disease (IBD). Prophylactic premedication (PM) with corticosteroids or antihistamines prior to IFX infusions has been used in clinical practice, but its efficacy is not known. The aim of this study was to assess the influence of steroid PM on IR incidence in pediatric patients with IBD receiving IFX. Methods: We performed a case–control study that included pediatric patients with IBD receiving IFX. Patients were divided into four subgroups according to the agent and PM they received: Remicade (original drug) + PM, and two biosimilars—Reshma +/− PM, and Flixabi—PM. At our site, until 2018, PM with steroids was used as a part of standard IFX infusion (PM+); however, since then, this method has no longer been administered (PM−). IRs were divided into mild/severe reactions. Differences between subgroups were assessed with the appropriate chi-square test. Multivariate logistic regression was used to assess associations between PM and IR incidence, correcting for co-medication usage. Results: There were 105 children (55 PM+, 44 male, mean age 15 years) included in the study who received 1276 infusions. There was no difference between the PM+ and PM− subgroups, either in incidence of IR (18.2% vs. 16.0% of patients, p > 0.05) or in percentage of infusions followed by IR (2.02% vs. 1.02% of infusions, p > 0.5). The OR of developing IR when using PM was 0.34, and the difference in IRs ratio in PM+ and PM− patients was not statistically significant (95% CI, 0.034–1.9). There were 11/18 (61.1%) severe IRs (anaphylactic shock) reported in all patients (both PM+ and PM−). Conclusion: At our site, the incidence of IR was low, and PM did not decrease the incidence of IR in pediatric patients with IBD receiving IFX. These results indicate that PM with steroids should not be a standard part of IFX infusion to prevent IR.

Sign in / Sign up

Export Citation Format

Share Document